Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
J Int Med Res. 2020 Jun;48(6):300060520928793. doi: 10.1177/0300060520928793.
The discovery of epidermal growth factor receptor () somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exist as compound mutations. A few reports have described the efficacy of first- and second-generation EGFR-TKIs. However, the efficacy of osimertinib in patients with these uncommon compound mutations is unknown. In this study, we reported the postoperative outcome of a patient with NSCLC and uncommon compound G719X and S768I mutations. After postoperative recurrence, the patient was treated with osimertinib, and an excellent and long-lasting clinical response was achieved. The patient has taken osimertinib for 31.0 months and exhibited a partial response, and her follow-up is ongoing.
表皮生长因子受体（）体细胞突变的发现和酪氨酸激酶抑制剂（TKIs）作为靶向治疗药物的出现改变了晚期非小细胞肺癌（NSCLC）的治疗前景。G719X 和 S768I 是罕见的突变，它们通常作为复合突变存在。有一些报告描述了第一代和第二代 EGFR-TKIs 的疗效。然而，奥希替尼在这些罕见的复合突变患者中的疗效尚不清楚。在本研究中，我们报告了一例非小细胞肺癌伴罕见复合 G719X 和 S768I 突变患者的术后结果。术后复发后，该患者接受奥希替尼治疗，取得了极好且持久的临床反应。该患者服用奥希替尼 31.0 个月，部分缓解，随访仍在继续。
